Best of ASCO - 2014 Annual Meeting

 

Welcome

Late and Long-Term Effects

Patient and Survivor Care

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A case series of immune checkpoint inhibitor induced diabetes mellitus (ICI-DM).

Venessa H Tsang

e22080

A longitudinal assessment to evaluate the impact of higher body mass index on cancer-related fatigue in breast cancer patients receiving chemotherapy.

Julia Ellen Inglis

10061

Adverse health outcomes (AHO) after modern cisplatin-based chemotherapy (CHEM) compared to surgery-only: A study of 503 testicular cancer survivors (TCS).

Nabil Adra

e22068

An attempt to better understand radiation recall events: A literature review.

Amin Benyounes

e22109

An individual patient level data pooled analysis of T-DM1 cardiac safety in HER2-positive (HER2+) metastatic breast cancer (MBC) patients.

Noam Falbel Ponde

10068

Cancer survivorship in hematologic malignancies: Lifestyle changes after diagnosis.

Pannaga G. Malalur

e22089

Cancer survivorship, financial wellbeing and food insecurity in the U.S.

Zhiyuan Zheng

10075

Cardiometabolic risk in childhood cancer survivors: A Children's Oncology Group study.

Emma Lipshultz

10056

Cardioprotective effect and safety of dexrazoxane in all breast cancer stages in patients treated with anthracyclines with or without trastuzumab: A systematic review and meta-analysis.

Ariane Macedo

10072

Changes in the microbiome induced by adjuvant chemotherapy for breast and gynecological cancer and their association with weight gain.

Ayelet Shai

e22113

Characterization of the onset of thyroid function (TF) abnormalities in patients receiving immune checkpoint inhibitor (CPI) therapy.

Radowan Elnair

e22082

Chronic thrombocytopenia in cancer patients: Impact on percutaneous coronary intervention and antiplatelet therapy.

Dinu Valentin Balanescu

e22092

Clinical outcomes after fractional flow reserve-guided treatment of oncology patients.

Teodora Donisan

e22106

Cognitive declines in relationship with severe hypogonadism in long-term testicular germ cell tumor survivors: A prospective survivorship study.

Michal Chovanec

e22104

Cumulative burden of severe chronic health conditions (CHC) and health related quality of life (HRQoL) among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort study (SJLIFE).

Nickhill Bhakta

10078

Depomedroxyprogesterone therapy for hot flashes in survivors of ER-expressing breast cancer: Impact on recurrence and survival.

Natalie Ertz-Archambault

e22116

Diabetes outcomes in patients with breast cancer.

Martin W. Schoen

e22078

Does ethnicity influence cardiac survival among cancer patients?

Muneer J Al-Husseini

e22114

Early retirement after return to work among cancer survivors: A population based study.

Yakir Rottenberg

e22064

Effect of comorbidities on outcomes in colorectal cancer (CRC) survivors.

Colleen A Cuthbert

10055

Effect of pneumocystis jirovecii pneumonia (PJP) on morbidity and mortality in oncology patients: A single centre experience.

Timothy Dudley Clay

e22088

Efficacy of haloperidol versus olanzapine for control of chemotherapy induced nausea and vomiting.

Soniya Dulal

10053

Expression of kynurenine aminotransferase I as a prognostic factor in the context of the occurrence of neurological symptoms during chemotherapy.

Rodryg Ramlau

e22081

Fear of recurrence as a triage strategy to identify testicular cancer survivors in need of psychological interventions.

Hector De La Mora

e22110

Fertility preservation in female oncology patients: Factors influencing practice patterns.

Papri Sarkar

e22108

Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).

Michael Friedlander

10062

Hypogonadism and effects on quality of life in previously treated germ cell tumor survivors: A single-centre, non-randomized, prospective observational study.

Nabin Khanal

10079

Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial.

Samuel Martel

10067

Impact of cancer on employment and finances in young adult (YA) survivors.

Tyler Garrett Ketterl

10013

Incidence and characteristics of adrenal insufficiency following immune checkpoint inhibitor therapy for melanoma.

Logan Rhea

e22077

Incidence of nonvalvular atrial fibrillation on ibrutinib compared to other tyrosine kinase inhibitors: A large multi-institution general practice study.

Joyce Njoroge

e22076

Increased hypercalcemia trend.

Zachary Michael Trisel

e22117

Independent prognostic value of the EORTC QLQ-C30 summary score on all-cause mortality: Results from the population-based PROFILES registry.

Olga Husson

10070

Investigating nerve fibre damage in chemotherapy-induced peripheral neuropathy (CIPN): A prospective study.

Sabrina Ramnarine

e22096

Long-term platinum (Pt) change and its associations with cisplatin-related late effects in testicular cancer survivors (TCSs).

Hege Sagstuen Haugnes

e22067

Meta-analysis of the cardiac events in the adjuvant trastuzumab trials.

Evandro De Azambuja

10066

Metabolic syndrome in adult survivors of childhood cancer.

Aruna Alahari Dhir

e22102

Neuromuscular ultrasound for assessment of peripheral neuropathy in breast cancer patients receiving taxane therapy.

Thomas Lycan

e22083

Obesity at diagnosis and after treatment in breast cancer survivors and risk of neuropathy.

Jennifer Y. Sheng

e22085

Oncology patients referred for cognitive training in a military treatment facility: Demographics, symptom reporting and cognitive functioning for CNS and non CNS cancers.

Katherine Sullivan

10076

Optical topography of cognitive tasks-based hemodynamic responses in the prefrontal cortex.

Pascal Jean-Pierre

e22066

Outcomes of immune-checkpoint inhibitor induced organ toxicities.

Hamzah Abu Sbeih

10063

Patient characteristics and correlation with sexual functioning and quality of life among female cancer survivors: Results of the WFU CCOP Research Base Protocol 97106.

Nevine M. Hanna

e22094

Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated thrombosis.

Robert Adam Schmidt

10057

Patient driven efforts for quality outcomes and research in head and neck cancer.

Ayaka J. Iwata

e22065

Patient’s perspective of living with and beyond the treatment of trastuzumab: Results from the PERSEPHONE early breast cancer trial.

Janet Dunn

e22101

Patient-reported outcomes following autologous stem cell transplantation for patients with multiple myeloma.

Noa Biran

e22069

Pharmacokinetic (PK) modeling of serum platinum to reveal extent of long-term exposure and associated comorbidities after cisplatin treatment.

Omar El Charif

10058

Pilot trial of epidermal growth factor (EGF) ointment for the patients with epidermal growth factor receptor (EGFR) inhibitor related skin side effects.

Sung Yong Oh

10054

Predictors of long-term follow-up care (LTFU) among survivors of adolescent and young adult (AYA) cancers: A population-based study in the IMPACT cohort.

Dalia Kagramanov

10014

Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Matteo Lambertini

10065

Prevalence and predictors of decreased cardiorespiratory fitness among cancer patients.

Jesse Pittard Caron

10071

Prevalence of urinary symptoms in women with early-stage breast cancer and treatment with (neo)adjuvant chemotherapy.

Joanne E. Mortimer

e22098

Pulmonary events in patients with Hodgkin lymphoma after first line chemotherapy in the US Department of Defense (DOD) healthcare system.

Tod A. Morris

e22070

Quality of life issues in long-term testicular germ cell tumor survivors.

Michal Chovanec

e22107

Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I): An ACCRU trial.

Kathryn Jean Ruddy

e22075

Risk factors for the development of atrial fibrillation on ibrutinib treatment.

Robert William Lentz

10059

Risk of chronic comorbidities in survivors of adolescent and young adult cancer (AYA).

Chun Chao

10015

Risk of gastrointestinal and hepatic toxicities in patients with cancer treated with regorafenib: A systematic review and meta- analysis of randomized controlled trials.

Rachana Yendala

e22118

Risk of solid cancer after treatment for testicular germ cell cancer in the platinum era.

Michael Schaapveld

10069

Self-reported functional assessment by patients receiving different prostate cancer strategies: Five-year results from the VICAN large prospective cohort.

G Raldine Pignot

10077

Surviving cancer between demoralization and hope: A cross-sectional assessment and clinical implications.

Mario Airoldi

e22071

Symptom burden and employment status in breast cancer (BC) survivors.

Ines Maria Vaz Duarte Luis

10073

Symptoms burden reported by head and neck cancer patients at their first survivorship clinic visit.

Guadalupe R. Palos

e22090

The effect of neutropenic diets on infection and mortality rates in cancer patients: An updated systematic review and meta- analysis.

Mohamad B. Sonbol

e22087

The relationship between chemotherapy-induced neuropathy and quality of life in breast cancer survivors.

Barbara Sharon Gordon

e22111

Topical sildenafil in the treatment of hand-foot syndrome and hand-foot skin reaction: A retrospective study.

Christy Arrowood

e22095

Trajectory of recurrent falls in postmenopausal breast cancer survivors and matched cancer-free controls.

Kathy Pan

e22100

Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors.

Jennifer Wu

e22093

Treatment related radiation toxicity among cervical cancer patients.

Lisa A. Rubinsak

e22072

Ultra-low doses of TX-004HR to improve symptoms of vulvar and vaginal atrophy (VVA) while maintaining serum levels of estradiol within the normal postmenopausal range.

Shari Beth Goldfarb

10074

Utilization of bioimpedance spectroscopy (BIS) to reduce rates of breast cancer related lymphedema (BCRL) in extremely high-risk patients.

Sharon Wing Wai Chan

e22112

Vaginal laser to improve symptomatic vulvovaginal atrophy and sexual function in breast cancer patients: Report from LAAVA pilot study.

Antonia Pearson

10064